Mark S Fineman
2PUBLICATIONS
4CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (2)
Sort by Publication Date:
|Aug 06, 2025
GLY-200, an oral pharmacologic duodenal exclusion drug, resulted in positive effects on glucose, lipids and bodyweight in patients with type 2 diabetes: Results of a randomized, double-blind placebo-controlled trial.Christine L N Bryant, Kevin Colbert, Marcus Hompesch
|Jun 28, 2023
First-in-human study of a pharmacological duodenal exclusion therapy shows reduced postprandial glucose and insulin and increased bile acid and gut hormone concentrations.Mark S Fineman, Christine L N Bryant, Kevin Colbert
Pageof 1
